NVST

Envista Holdings Corp NVST

NYSEMid CapHealthcare

13F Pro quality score

Rank #1,289 of 2,925TOP 50%

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$730.50M

Quarter to Jul 3

Net income

$53.70M

Quarter to Jul 3

Free cash flow

$104.30M

Quarter to Jul 3

Operating margin

11.0%

Quarter to Jul 3

Top Institutional Holders

as of Q2 2026
$5.48B total

What's Driving NVST's Business? Latest 10-Q Breakdown

21/21 datapoints verified

AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended July 3, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Envista Q2 revenue grew 7.1% to $730.5M with operating profit surging 73.4% to $80.3M, driven by 5.0% core sales growth and $12.6M in tariff refunds.

Biggest Revenue Drivers

Specialty Products & Technologies$471.0M+5.8% YoY

Dental implant systems, regenerative solutions, orthodontic brackets, and aligners grew from volume increase of 2.0% and price increase of 1.1%.

Equipment & Consumables$259.5M+9.5% YoY

Digital imaging systems, endodontic systems, restorative materials grew from volume increase of 5.5% and price increase of 3.0%.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/NVST

Earnings Per Share

13fpro.ai/company/NVST

Loading ratio trend…

NVST key financials by period

Reported revenue, net income and operating margin by fiscal year, from Envista Holdings Corp's annual filings on SEC EDGAR.

Envista Holdings Corp reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$2.7B$47.0M8.0%
FY 2024$2.5B$-1.1B-41.3%
FY 2023$2.6B$-100.2M1.2%
FY 2022$2.6B$243.1M12.4%
FY 2021$2.5B$340.5M12.2%
FY 2020$1.9B$33.3M2.3%
Source: NVST filings on SEC EDGAR →

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

NVST insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in NVST

1 transaction in NVST reported by 1 member of Congress under the STOCK Act, most recent trade Jun 6, 2024. Reported transactions, not recommendations.

All Congress stock trades →

About Envista Holdings Corp (NVST): stock profile, AI score and financials

Envista Holdings Corp (NVST) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NVST at 54.9/100 on a composite quality score built from its SEC filings, placing it at rank #1,289 of 2,925 stocks — the top half of the AI-ranked universe. NVST scores in the top quartile across earnings quality (91.4). Areas of concern include institutional flow (27.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 47.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Envista Holdings Corp reports quarterly revenue of $730.5M, net income of $53.7M, an operating margin of 11.0%. Top institutional holders of NVST by reported 13-F value include BlackRock, ARIEL INVESTMENTS, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. NVST trades on the NYSE exchange and files with the SEC under CIK 1757073. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Envista Holdings Corp directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1757073 →